Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T23:59:33.989Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of a Reversible Monoamine Oxidase-A Inhibitor (Moclobemide) on Sleep of Depressed Patients

Published online by Cambridge University Press:  06 August 2018

J. M. Monti
J. M. Monti*
Affiliation:
Department of Pharmacology & Therapeutics, School of Medicine, Clinics Hospital, Montevideo, Uruguay
Get access Rights & Permissions [Opens in a new window]

Abstract

The effect of moclobemide, a short-acting, reversible, preferential monoamine oxidase-A inhibitor in a 4-week therapeutic trial, on the sleep of ten depressed patients, was assessed by polysomnographic recordings. Compared with their time on placebo, patients receiving moclobemide showed improved sleep continuity, particularly during the intermediate and late stages of drug administration. The total increase in sleep time was comprised of larger amounts of stage 2 non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. Withdrawal of moclobemide was followed by a further increase of REM sleep, although values did not surpass those sometimes observed in adults with normal sleep. In these patients, the symptoms of depression were rated as being significantly improved during the study period.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S6: Depression and Reversible Monoamine Oxidase Inhibitors-New Perspectives , October 1989 , pp. 61 - 65
Copyright
Copyright © 1989 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Akindele, M.O., Evans, J.I. & Oswald, I. (1970) Mono-amine oxidase inhibitors, sleep and mood. Electroencephalography and Clinical Neurophysiology, 29, 47–56.CrossRefGoogle ScholarPubMed
Amrein, R., Allen, S.R., Vranesic, D., et al (1988) Antidepressant drug therapy: associated risks. Journal of Neural Transmission, 26 (Suppl.), 73–86.Google Scholar
Brebbia, D.R., Branchey, M.H., Pyne, E., et al (1975) The effects of amoxapine on electroencephalographic stages of sleep in normal human subjects. Psychopharmacologia, 45, 1–7.CrossRefGoogle Scholar
Da Prada, M., Zürcher, G., Wüthrich, I., et al (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. Journal of Neural Transmission, 26 (Suppl.), 31–56.Google Scholar
Di Perri, R., Mailland, F. & Bramanti, P. (1986) The effects of amineptine on the mood and nocturnal sleep of depressed patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 11, 65–70.CrossRefGoogle Scholar
Dunleavy, D.L.F. & Oswald, I. (1973) Phenelzine, mood response, and sleep. Archives of General Psychiatry, 28, 353–356.CrossRefGoogle ScholarPubMed
Dunleavy, D.L.F., Brezinova, V., Oswald, I., et al (1972) Changes during weeks in effects of tricyclic drugs on the human sleeping brain. British Journal of Psychiatry, 120, 663–672.CrossRefGoogle ScholarPubMed
Gillin, J.C., Wyatt, R.J., Fram, D., et al (1978) The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacology, 59, 267–272.CrossRefGoogle ScholarPubMed
Gillin, J.C., Sitaram, N., Wehr, T., et al (1984) In Neurobiology of Mood Disorders (eds Post, R.M. & Ballenger, J.C.). Baltimore: Williams & Wilkins.Google Scholar
Gold, P.W., Goodwin, F.K. & Chrousos, G.P. (1988) Clinical and biochemical manifestations of depression. New England Journal of Medicine, 319, 413–420.Google Scholar
Hoff, P., Golling, H., Kapfhammer, H.P., et al (1986) Cimoxatone and moclobemide, two new MAO-inhibitors: influence on sleep parameters in patients with major depressive disorder. Pharmacopsychiatry, 19, 249–250.Google Scholar
Kupfer, D.J., Spiker, D.G., Coble, P.A., et al (1981) Sleep and treatment prediction in endogenous depression. American Journal of Psychiatry, 138, 429–434.Google Scholar
Kupfer, D.J., Hanin, I., Coble, P.A., et al (1982) EEG sleep and tricyclic blood levels: Acute and chronic administration in depression. Journal of Clinical Psychopharmacology, 2, 8–13.Google Scholar
Kupfer, D.J., Spiker, D.G., Rossi, A., et al (1983) Recent diagnostic and treatment advances in REM sleep and depression. In Treatment of Depression: Old Controversies and New Approaches (eds Clayton, P. & Barrett, J.). New York: Raven Press.Google Scholar
Le Gassicke, J., Ashcroft, G.W., Eccleston, D., et al (1965) The clinical state, sleep and amine metabolism of a tranylcypromine (Parnate) addict. British Journal of Psychiatry, 111, 357–364.Google Scholar
Mendlewicz, J., Dunbar, G.C. & Hoffman, G. (1985) Changes in sleep EEG architecture during the treatment of depressed patients with mianserin. Acta Psychiatrica Scandinavica, 72 (Suppl. 320), 26–29.CrossRefGoogle Scholar
Montgomery, I., Old, I., Morgan, K., et al (1983) Trazodone enhances sleep in subjective quality but not in objective duration. British Journal of Clinical Pharmacology, 16, 139–144.CrossRefGoogle ScholarPubMed
Mouret, J., Lemoine, P., Minuit, M.P., et al (1988) Effects of trazodone on the sleep of depressed subjects — a poly graphic study. Psychopharmacology, 95, S37–S43.Google Scholar
Passouant, P., Cadilhac, J., Billiard, M., et al (1973) La suppression du sommeil paradoxal par la clomipramine. Thérapie, 28, 379–392.Google ScholarPubMed
Rechtschaffen, A. & Kales, A. (1968) A manual of standardized terminology, techniques and scoring system for sleep stages in human subjects. National Institutes of Health Publication 204. Washington DC: US Government Printing Office.Google Scholar
Reynolds, C.F. & Kupfer, D.J. (1987) Sleep research in affective illness: state of the art circa 1987. Sleep, 10, 199–215.Google Scholar
Ritvo, E.R., Ornitz, E.M., La Franchi, S., et al (1967) Effects of imipramine on the sleep-dream cycle: an EEG study in boys. Electroencephalography & Clinical Neurophysiology, 22, 465–468.CrossRefGoogle ScholarPubMed
Shipley, J.E., Kupfer, D.J., Griffin, S.J., et al (1985) Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients. Psychopharmacology, 85, 14–22.Google Scholar
Steiger, A., Holsboer, F., Gerken, A., et al (1987) Results of an open clinical trial of brofaromine (CGP 11 305A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry, 20, 262–269.Google Scholar
Tormey, W.P., Buckley, M.P., O'Kelly, D.A., et al (1980) Sleep and endocrine profile of the antidepressant mianserin. Current Medical Research & Opinion, 6, 456–460.Google Scholar
Vogel, G.W., Vogel, F. & McAbee, R.S. (1980) Improvement of depression by REM sleep deprivation. New findings and a theory. Archives of General Psychiatry, 37, 247–253.Google Scholar
Wiegand, M., Berger, M., Zulley, J., et al (1986) The effect of trimipramine on sleep in patients with major depressive disorder. Pharmacopsychiatry, 19, 198–199.CrossRefGoogle Scholar
Wyatt, J., Fram, D.H., Kupfer, D.J., et al (1971) Total prolonged drug-induced REM sleep suppression in anxious-depressed patients. Archives of General Psychiatry, 24, 145–155.Google Scholar
Zung, W.W.K. (1980) A comparison of the effects of viloxazine and placebo on the sleep of depressed patients. Current Therapeutic Research, 27, 152–156.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.